Arcus Biosciences

Company snapshot

Arcus Biosciences maintains 53 tracked programs across Advanced Cancer, Non-small Cell Lung Cancer, Metastatic Clear Cell Renal Cell Carcinoma, TNBC - Triple-Negative Breast Cancer, Metastatic Esophageal or Gastric Cancer, Esophageal or Gastric Cancer, Solid Tumors, Clear Cell Renal Cell Carcinoma, Metastatic colorectal cancer, Melanoma, Advanced Solid Tumor, Advanced Pancreatic Cancer, Metastatic

• 53 active pipeline program(s) linked via ClinicalTrials.gov.
• 30 US patent(s) indexed to this assignee profile.
• 53 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Arcus Biosciences. Not investment advice.

• trial_data Jun 8, 2026

  Arcus Biosciences pipeline update: casdatifan, quemliclustat, domvanalimab

• Peer + 0 momentum

  Regeneron UK

  TA overlap score 40

• Peer + 0 momentum

  Bristol Myers Squibb

  TA overlap score 38

• Peer + 0 momentum

  Daiichi Sankyo US

  TA overlap score 31.6

• Peer + 0 momentum

  Nektar Therapeutics UK

  TA overlap score 31.4

• Peer + 0 momentum

  Summit Therapeutics

  TA overlap score 28.2

• Peer + 0 momentum

  Alaunos Therapeutics

  TA overlap score 26.8

• Peer + 0 momentum

  Coherus Oncology

  TA overlap score 25

• Peer + 0 momentum

  BioNTech SE

  TA overlap score 24.6

• Peer + 0 momentum

  Aprea Therapeutics

  TA overlap score 23

Recent activity

Latest pipeline, patent, and corporate events for Arcus Biosciences.

1. Jun 8, 2026 Clinical update

   ARC-12 — Phase 1

2. Jun 8, 2026 Clinical update

   ARC-20 — Phase 1

3. Jun 8, 2026 Clinical update

   ARC-10 — Phase 3

4. Jun 8, 2026 Clinical update

   STAR-221 — Phase 3

5. Jun 8, 2026 Clinical update

   PRISM-1 — Phase 3

View all clinical trial activity →

• What is Arcus Biosciences?

  Arcus Biosciences is a pharma organization headquartered in Hayward, USA. It trades on NYSE under ticker RCUS. Primary therapeutic focus areas include Advanced Cancer, Non-small Cell Lung Cancer, Metastatic Clear Cell Renal Cell Carcinoma, TNBC - Triple-Negative Breast Cancer, Me

• Is Arcus Biosciences publicly traded?

  Yes. Arcus Biosciences is listed with ticker RCUS on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Arcus Biosciences develop or market?

  We link 25 drug profile(s) where Arcus Biosciences is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/arcus-biosciences#company-drugs.

• What are the latest developments for Arcus Biosciences?

  In the last 12 months our linked public records show 53 trial program update(s) and 3 US patent grant(s) tied to this profile.

• What therapeutic areas does Arcus Biosciences focus on?

  Arcus Biosciences focuses on Advanced Cancer, Non-small Cell Lung Cancer, Metastatic Clear Cell Renal Cell Carcinoma based on our analysis of their pipeline programs and drug development activities.